Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No Breathing Room For Advair: GSK Combo Part Of Asthma Drug Restrictions

Executive Summary

GlaxoSmithKline's asthma combination product Advair is included in an FDA advisory against first-line use of long-acting beta agonist bronchodilators despite an advisory committee review that suggested Advair was less risky than other products

You may also be interested in...



FDA To Conduct Pediatric Safety Analysis for Serevent, Other LABAs

FDA will complete a risk/benefit analysis for pediatric use of GlaxoSmithKline's Serevent (salmeterol) as soon as possible, Pediatric Therapeutics Director Dianne Murphy assured the agency's Pediatrics Advisory Committee Nov. 28

FDA To Conduct Pediatric Safety Analysis for Serevent, Other LABAs

FDA will complete a risk/benefit analysis for pediatric use of GlaxoSmithKline's Serevent (salmeterol) as soon as possible, Pediatric Therapeutics Director Dianne Murphy assured the agency's Pediatrics Advisory Committee Nov. 28

NIH Asthma Guide Concurs With FDA In Supporting LABAs For Adjunctive Use

Sales of combination inhaled corticosteroid/long-acting beta2-agonists may receive a boost from NIH guidelines endorsing their use as adjunctive therapy in certain asthma patients

Related Content

Topics

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel